RCAP
JAZZ icon

Resolute Capital Asset Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Resolute Capital Asset Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$6.8M – 54
2025
Q4 		$6.8M Buy
+40,000
New +$6.13M 3.29% 8

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Resolute Capital Asset Partners's JAZZ Position: Q1 2026 in Review

Resolute Capital Asset Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 40,000 shares — an estimated $6.8M sold.

Resolute Capital Asset Partners first reported a position in JAZZ in Q4 2025 and held it in 1 quarter. The position peaked at $6.8M in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Resolute Capital Asset Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 40,000 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.8M.
  • Resolute Capital Asset Partners first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Resolute Capital Asset Partners's Jazz Pharmaceuticals position peaked at $6.8M in Q4 2025.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2026, filed 15 May 2026.